The Centers for Medicare and Medicaid Innovation is introducing new pay models that will shift primary care from fee-for-service payments to a global fee model under which clinicians and hospitals could assume varying amounts of risk.
A team of Dutch investigators enrolled 18 multifocal motor neuropathy (MMN) patients on intravenous immune globulin(IVIG) treatment in a prospective open-label study to evaluate the comparative safety of treatment with 10% human immune globulin whose subcutaneous administration is facilitated with recombinant human hyaluronidase (fSCIG) (HyQvia).
Canadian investigators at Ottawa Hospital have reported a very high success rate with a nurse-led individualized program to facilitate a smooth transition in patients with neurological disorders from chronic intravenous immune globulin (IVIG) to subcutaneous immune globulin (SCIG) treatment.
Researchers at the University of Melbourne have discovered immune cells that can fight all different kinds of the influenza (flu) virus.
A study out of the University of Texas Southwestern Medical Center found a 96 percent response rate to treatment with therapeutic plasma exchange (PLEX) in a series of 58 consecutive myasthenia gravis (MG) patients, with no significant difference in response between those with or without autoantibodies.
CMS has launched the Artificial Intelligence Health Outcomes Challenge, a three-stage competition to accelerate artificial intelligence solutions that will potentially be used by CMS’s Innovation Center.
The FDA is making efforts as part of its Youth Tobacco Prevention Plan to ensure no tobacco products are marketed to, sold to or used by kids.
Two studies suggest low serum albumin levels in patients with sepsis is associated with mortality.
CMS has finalized its rule to give Medicare Advantage plans a 2.53 percent pay raise in 2020, up from its original plan to raise pay 1.59 percent.
CMS announced the Part D Payment Modernization Model to share in savings generated by reducing costs in the program's catastrophic phase.
In 2018, HHS awarded $2.34 billion in Ryan White HIV/AIDS Program grants to cities, counties, states and local community based organizations.
Valneva USA has received FDA approval of an accelerated dosing regimen for IXIARO (Japanese encephalitis vaccine, inactivated, adsorbed).
